Association of chronic obstructive pulmonary disease with coronary artery disease

Chinese Medical Journal

Volumn 126, Issue 17, 2013, Pages 3205-3208

  Liang, Bin Miao ^a   Xu, Zhi Bo ^b   Yi, Qun ^a   Ou, Xue Mei ^a   Feng, Yu Lin ^a  

^a SICHUAN UNIVERSITY   (China)

^b Second People's Hospital of Chengdu   (China)

Author keywords

Chronic obstructive pulmonary disease; Coronary artery disease; Multi detector computed tomography

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; IOPAMIDOL; LOW DENSITY LIPOPROTEIN; SALBUTAMOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; RISK FACTOR; SMOKING; SPIROMETRY; VASCULAR DISEASE;

CORONARY ARTERY DISEASE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84883505948     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131415     Document Type: Article

References (24)

1. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
2. Leschka S, Alkadhi H, Plass A, Desbiolles L, Grünenfelder J, Marincek B, et al. Accuracy of MSCT coronary angiography with 64-slice technology: first experience. Eur Heart J 2005; 26: 1482-1487.
3. Tan KT, Reed D, Howe J, Challenor V, Gibson M, McGann G. CT vs. conventional angiography in unselected patients with suspected coronary heart disease. Int J Cardiol 2007; 121: 125-126.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
5. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656-664.
6. Engstrom G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002; 106: 2555-2560.
7. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
8. Zheng J, Zhong N. Normative values for pulmonary function testing in Chinese adults. Chin Med J 2002; 115: 50-54.
9. Nishiyama K, Morimoto T, Furukawa Y, Nakagawa Y, Ehara N, Taniguchi R, et al. Chronic obstructive pulmonary disease-an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int J Cardiol 2010; 143: 178-183.
10. Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96: 756-759.
11. Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 2004; 94: 649-651.
12. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
13. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
14. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006; 12: 106-112.
15. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J 2006; 27: 877-879.
16. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 367-370.
17. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
18. Topsakal R, Kalay N, Ozdogru I, Cetinkaya Y, Oymak S, Kaya MG, et al. Effects of chronic obstructive pulmonary disease on coronary atherosclerosis. Heart Vessels 2009; 24: 164-168.
19. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
20. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004; 59: 574-580.
21. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
22. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874.
23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
24. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930-1937.